DEERFIELD MANAGEMENT COMPANY, L.P.
New York, NY · CIK 1009258 · 13F filing filed 2021-08-16
SEC-registered investment adviser since 2012 · limited partnership
- Assets managed$19.1bn
- Staff189 · 89 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds12 (11 hedge) · $19.2bn gross assets
- Form ADV · 2026-07-31SEC adviser record
- Legal entityDEERFIELD MANAGEMENT COMPANY, L.P. (US)
- Kindhedge funds, private equity, futures
- Others nearbyNew York, NY, Parsippany, NJ
As an employer
- Offices in1 country
- Private fundshedge 11, private equity 1
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| New York, NY (main office)United States | about 86 |
| Parsippany, NJUnited States | 3 |
US visa salary filings
- Filings FY2024–20266
- Median salary offered$160,000
- Middle half$140,000 – $191,250
- Job titles5
| Job title | Filings | Median |
|---|---|---|
| AnalystNew York, NY | 2 | $140,000 |
| Data EngineerNew York, NY | 1 | $210,000 |
| Senior Director, Business IntelligenceNew York, NY | 1 | $195,000 |
| Director, Business IntelligenceNew York, NY | 1 | $180,000 |
| Market Research AssociateNew York, NY | 1 | $80,000 |
Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Deerfield Management Company, L.P..
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
This report includes the holdings of 1 other manager that shares the investment decisions:
- Flynn Management LLC – reports through this filing
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2021
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| VIATRIS INC VTRS | $269.0m4.78% | Added +1.6m |
| SINGULAR GENOMICS SYSTEMS IN COM | $250.4m4.45% | New |
| INVITAE CORP NVTA 2 09.01.24 · principal | $221.7m3.94% | Unchanged |
| CAREMAX INC COM CL A | $216.4m3.84% | New |
| ADAPTHEALTH CORP AHCO | $201.6m3.58% | Added +5.1m |
| AERIE PHARMACEUTICALS INC AERI 1.5 10.01.24 · principal | $156.6m2.78% | Added +7.8m |
| GLAUKOS CORP GKOS 2.75 06.15.27 · principal | $153.5m2.73% | New |
| NATERA INC NTRA 2.25 05.01.27 · principal | $136.3m2.42% | New |
| BRIDGEBIO PHARMA INC BBIO 2.5 03.15.27 · principal | $131.2m2.33% | Unchanged |
| ORGANOGENESIS HLDGS INC ORGO | $120.0m2.13% | Added +4.2m |
| ENVISTA HOLDINGS CORPORATION NVST 2.375 06.01.25 · principal | $112.0m1.99% | New |
| NUVASIVE INC GMED 1 06.01.23 · principal | $101.3m1.80% | New |
| EDGEWISE THERAPEUTICS INC EWTX | $83.9m1.49% | Unchanged |
| PULMONX CORP LUNG | $79.5m1.41% | Added +863.9k |
| INSULET CORP PODD 0.375 09.01.26 · principal | $78.2m1.39% | Unchanged |
| APELLIS PHARMACEUTICALS INC APLS 3.5 09.15.26 · principal | $77.8m1.38% | Added +20.0m |
| ACUTUS MED INC AFIB | $73.7m1.31% | Unchanged |
| CENTENE CORP DEL CNC | $72.6m1.29% | Reduced -990.6k |
| NEUROCRINE BIOSCIENCES INC NBIX | $70.6m1.25% | Unchanged |
| PACIRA BIOSCIENCES INC PCRX | $69.6m1.24% | Reduced -18.0k |
| PROTAGONIST THERAPEUTICS INC PTGX | $61.2m1.09% | Added +104.0k |
| MIRUM PHARMACEUTICALS INC MIRM | $59.6m1.06% | Unchanged |
| MOLINA HEALTHCARE INC MOH | $58.7m1.04% | Unchanged |
| LARIMAR THERAPEUTICS INC LRMR | $57.3m1.02% | Added +685.7k |
| INSMED INC INSM 0.75 06.01.28 · principal | $55.5m0.99% | New |
| SILK RD MED INC SILK | $54.5m0.97% | Added +650.0k |
| ZIMMER BIOMET HOLDINGS INC ZBH | $54.4m0.97% | Reduced -19.0k |
| CONSTELLATION PHARMCETICLS I CNST | $54.1m0.96% | Reduced -107.5k |
| INSMED INC INSM 1.75 01.15.25 · principal | $52.5m0.93% | Reduced -11.0m |
| QUIDEL CORP QDEL | $52.4m0.93% | New |
| ALPHATEC HLDGS INC ATEC | $52.1m0.93% | Added +200.5k |
| INTERCEPT PHARMACEUTICALS IN ICPT 3.25 07.01.23 · principal | $51.9m0.92% | Unchanged |
| KALVISTA PHARMACEUTICALS INC KALV | $51.8m0.92% | Added +1.1m |
| DFP HEALTHCARE ACQUISITNS CO COM CL A | $49.8m0.88% | Reduced -5.5m |
| REVOLUTION MEDICINES INC RVMD | $49.7m0.88% | Added +129.0k |
| DECIPHERA PHARMACEUTICALS IN DCPH | $49.2m0.87% | Added +815.0k |
| CLOVIS ONCOLOGY INC CLVS 2.5 09.15.21 · principal | $47.8m0.85% | Unchanged |
| SPRINGWORKS THERAPEUTICS INC SWTX | $46.0m0.82% | Unchanged |
| TABULA RASA HEALTHCARE INC TRHC 1.75 02.15.26 · principal | $45.6m0.81% | Unchanged |
| GALAPAGOS NV LKFT | $45.3m0.80% | New |
| BIOCRYST PHARMACEUTICALS INC BCRX | $44.8m0.80% | Added +229.6k |
| NOVAVAX INC NVAX 3.75 02.01.23 · principal | $44.6m0.79% | Unchanged |
| WEREWOLF THERAPEUTICS INC HOWL | $44.5m0.79% | New |
| APRIA INC COM | $44.0m0.78% | Added +372.9k |
| ONCORUS INC COM | $43.5m0.77% | Unchanged |
| REATA PHARMACEUTICALS INC RETA | $42.5m0.75% | Reduced -120.0k |
| OWENS & MINOR INC NEW ACH | $42.2m0.75% | Reduced -552.5k |
| NUVASIVE INC GMED 0.375 03.15.25 · principal | $39.6m0.70% | Unchanged |
| RHYTHM PHARMACEUTICALS INC RYTM | $39.0m0.69% | Unchanged |
| KURA ONCOLOGY INC KURA | $37.4m0.66% | New |
| INOZYME PHARMA INC COM | $37.1m0.66% | Added +215.0k |
| IVERIC BIO INC OPHT | $36.4m0.65% | Unchanged |
| PUMA BIOTECHNOLOGY INC PBYI | $34.6m0.61% | Unchanged |
| BIODELIVERY SCIENCES INTL IN BDSI | $34.1m0.61% | Unchanged |
| NUVATION BIO INC NUVB | $33.3m0.59% | Added +577.2k |
| WAVE LIFE SCIENCES LTD 96663EUR | $32.2m0.57% | Added +1.3m |
| MERIDIAN BIOSCIENCE INC VIVO | $31.6m0.56% | Added +535.0k |
| ORCHARD THERAPEUTICS PLC ORTX | $30.5m0.54% | Unchanged |
| ARDELYX INC ARDX | $28.9m0.51% | Added +1.2m |
| TERNS PHARMACEUTICALS INC COM | $28.8m0.51% | Unchanged |
| HEALTH CATALYST INC HCAT 2.5 04.15.25 · principal | $28.7m0.51% | New |
| GRAYBUG VISION INC COM SHS | $28.7m0.51% | Unchanged |
| XERIS PHARMACEUTICALS INC XERS 5 07.15.25 · principal | $28.5m0.51% | Unchanged |
| AMICUS THERAPEUTICS INC FOLD | $28.4m0.50% | Added +243.0k |
| ITAMAR MED LTD ITMR | $28.1m0.50% | Unchanged |
| GRAPHITE BIO INC GRPH | $27.9m0.49% | New |
| ACCELERON PHARMA INC XLRN | $27.5m0.49% | Unchanged |
| PMV PHARMACEUTICALS INC PMVP | $27.5m0.49% | Added +380.3k |
| CULLINAN THERAPEUTICS INC CGEM | $26.9m0.48% | New |
| XERIS PHARMACEUTICALS INC COM | $26.7m0.47% | Unchanged |
| FATE THERAPEUTICS INC FATE | $26.4m0.47% | Unchanged |
| BROOKDALE SR LIVING INC BKD | $26.1m0.46% | Reduced -4.2m |
| BLUEPRINT MEDICINES CORP BPMC | $24.8m0.44% | Added +72.8k |
| AVEANNA HEALTHCARE HLDGS INC AVAH | $24.7m0.44% | New |
| CYTOKINETICS INC CYTK | $24.5m0.44% | Reduced -1.3m |
| BRIGHT HEALTH GROUP INC COM | $24.0m0.43% | New |
| KINNATE BIOPHARMA INC KNTE | $23.7m0.42% | Added +675.0k |
| SPRUCE BIOSCIENCES INC COM | $22.9m0.41% | New |
| ALECTOR INC ALEC | $22.0m0.39% | Unchanged |
| INSTIL BIO INC COM | $21.6m0.38% | Unchanged |
| MONTES ARCHIMEDES ACQUISITIO UNIT 09/30/2025 | $21.3m0.38% | New |
| PROFOUND MED CORP PROF | $21.2m0.38% | Unchanged |
| NEVRO CORP NVRO 2.75 04.01.25 · principal | $20.9m0.37% | Unchanged |
| OUTSET MED INC OM | $20.0m0.36% | New |
| PHARVARIS N V PHVS | $19.2m0.34% | Unchanged |
| DAY ONE BIOPHARMACEUTICALS I COM | $18.6m0.33% | New |
| STEREOTAXIS INC STXS | $17.8m0.32% | New |
| JANUX THERAPEUTICS INC JANX | $17.5m0.31% | New |
| QUANTUM SI INC QSI | $17.2m0.30% | New |
| DYNE THERAPEUTICS INC DYN | $16.6m0.29% | Added +101.0k |
| AEROVATE THERAPEUTICS INC COM | $16.3m0.29% | New |
| PTC THERAPEUTICS INC PTCT 3 08.15.22 · principal | $15.6m0.28% | Unchanged |
| BLUEBIRD BIO INC COM | $15.4m0.27% | Unchanged |
| CHIMERIX INC CMRX | $14.5m0.26% | Unchanged |
| IMMUNOCORE HLDGS PLC IMCR | $14.1m0.25% | Added +189.1k |
| MEDAVAIL HOLDINGS INC MYOS | $14.0m0.25% | Unchanged |
| AVIDITY BIOSCIENCES INC RNA | $13.8m0.25% | Added +106.2k |
| BIOVENTUS INC BVS | $13.7m0.24% | Reduced -178.4k |
| PRIVIA HEALTH GROUP INC PRVA | $13.3m0.24% | New |
| AERIE PHARMACEUTICALS INC AERI | $13.2m0.23% | Added +331.7k |
Sold out since Q1 2021
| Security | Value then |
|---|---|
| NEVRO CORP NVRO 1.75 06.01.21 | $168.4m115.8m shares |
| BOSTON SCIENTIFIC CORP BSX | $110.4m2.9m shares |
| ALEXION PHARMACEUTICALS INC ALXN | $88.6m579.2k shares |
| BIOGEN INC BIIB | $86.7m310.0k shares |
| DEERFIELD HEALTHCARE TECH AC | $82.2m6.8m shares |
| ORTHO CLINICAL DIAGNOSTICS H OCDX | $45.4m2.4m shares |
| HILL ROM HLDGS INC HRC | $30.9m279.9k shares |
| SOTERA HEALTH CO SHC | $27.7m1.1m shares |
| GENERATION BIO CO | $25.6m897.8k shares |
| MONTES ARCHIMEDES ACQUISITIO | $20.4m2.0m shares |
| CERTARA INC CERT | $16.4m600.0k shares |
| PACIFIC BIOSCIENCES CALIF IN PACB | $15.6m468.0k shares |
| RUBIUS THERAPEUTICS INC RUBY | $14.6m550.0k shares |
| STRYKER CORPORATION SYK | $14.4m59.0k shares |
| HIGHCAPE CAP ACQUISITION COR | $12.9m1.0m shares |
| AUTOLUS THERAPEUTICS PLC AUTL | $12.3m2.1m shares |
| SIGNIFY HEALTH INC SGFY | $11.7m400.0k shares |
| BOLT BIOTHERAPEUTICS INC | $11.5m350.0k shares |
| NEURONETICS INC STIM | $11.4m919.0k shares |
| PETCO HEALTH & WELLNESS CO I WOOF | $11.1m500.0k shares |
| INNOVAGE HLDG CORP INNV | $7.7m300.0k shares |
| 4D MOLECULAR THERAPEUTICS IN FDMT | $6.5m150.0k shares |
| GRACELL BIOTECHNOLOGIES INC | $6.2m400.0k shares |
| SENSEI BIOTHERAPEUTICS INC SNSE | $5.4m375.0k shares |
| LANDOS BIOPHARMA INC | $4.3m450.0k shares |
Trades reported as a company insider in Q2 2021
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2021-06-30 | LARIMAR THERAPEUTICS INC Director · Through Deerfield Private Design Fund IV, L.P. | Bought | $2.0m228.6k shares |
| 2021-06-30 | LARIMAR THERAPEUTICS INC Director · Through Deerfield Healthcare Innovations Fund, L.P. | Bought | $2.0m228.6k shares |
| 2021-06-30 | LARIMAR THERAPEUTICS INC Director · Through Deerfield Private Design Fund III, L.P. | Bought | $2.0m228.6k shares |
| 2021-05-04 | WEREWOLF THERAPEUTICS INC 10% owner · Through Deerfield Partners, L.P. | Bought | $12.8m800.0k shares |